[{"id":"6875ca53-6d3a-4295-900b-d9b68a43e3c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04989946","created_at":"2023-12-21T18:18:35.344Z","updated_at":"2025-02-25T14:16:15.460Z","phase":"Phase 1/2","brief_title":"Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer","source_id_and_acronym":"NCT04989946","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" CD8","pipe":"","alterations":" ","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Libtayo (cemiplimab-rwlc) • Firmagon (degarelix) • fianlimab (REGN3767) • MVI-118"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 12/16/2021","start_date":" 12/16/2021","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2025-02-07"},{"id":"85a83785-b733-4534-88fe-4b08d1977f8f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04126070","created_at":"2021-01-18T20:09:27.547Z","updated_at":"2025-02-25T14:28:48.143Z","phase":"Phase 2","brief_title":"Nivolumab + Docetaxel + ADT in MHSPC Patients with DDRD or Inflamed Tumors","source_id_and_acronym":"NCT04126070","lead_sponsor":"Xiao X. Wei, MD","biomarkers":" PD-L1 • BRCA1 • MSI • CD8 • MLH1 • MSH6 • MSH2 • CDK12 • CHEK2 • BRIP1 • RAD51C • RAD51D • NBN • ABRAXAS1 • GEN1","pipe":" | ","alterations":" PD-L1 expression • MSI-H/dMMR","tags":["PD-L1 • BRCA1 • MSI • CD8 • MLH1 • MSH6 • MSH2 • CDK12 • CHEK2 • BRIP1 • RAD51C • RAD51D • NBN • ABRAXAS1 • GEN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • docetaxel • goserelin acetate • Firmagon (degarelix) • leuprolide acetate for depot suspension"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 05/11/2020","start_date":" 05/11/2020","primary_txt":" Primary completion: 10/24/2024","primary_completion_date":" 10/24/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-01-29"},{"id":"9f5673ee-f7a4-40b1-ace8-59a97f2bd04f","acronym":"","url":"https://clinicaltrials.gov/study/NCT01990196","created_at":"2021-01-18T09:04:40.027Z","updated_at":"2025-02-25T13:10:58.081Z","phase":"Phase 2","brief_title":"Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer","source_id_and_acronym":"NCT01990196","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" VIM • CDH2","pipe":" | ","alterations":" VIM expression","tags":["VIM • CDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VIM expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • dasatinib • Xtandi (enzalutamide) • Firmagon (degarelix)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 09/23/2014","start_date":" 09/23/2014","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2024-10-01"},{"id":"63ba93fd-a0f6-4865-ad2d-03267b454c0a","acronym":"S1802","url":"https://clinicaltrials.gov/study/NCT03678025","created_at":"2021-07-05T17:17:10.086Z","updated_at":"2025-02-25T16:31:34.107Z","phase":"Phase 3","brief_title":"Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer","source_id_and_acronym":"NCT03678025 - S1802","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" SYP","pipe":"","alterations":" ","tags":["SYP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • abiraterone acetate • prednisone • Eligard (leuprolide acetate) • bicalutamide • triptorelin • goserelin acetate • flutamide • nilutamide • Firmagon (degarelix) • Viadur (leuprorelin implant)"],"overall_status":"Recruiting","enrollment":" Enrollment 1273","initiation":"Initiation: 09/24/2018","start_date":" 09/24/2018","primary_txt":" Primary completion: 04/01/2028","primary_completion_date":" 04/01/2028","study_txt":" Completion: 10/01/2031","study_completion_date":" 10/01/2031","last_update_posted":"2024-08-16"},{"id":"4004e195-6fa4-408f-8f56-450ccd6489c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06528210","created_at":"2025-02-25T16:02:53.341Z","updated_at":"2025-02-25T16:02:53.341Z","phase":"Phase 2","brief_title":"Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer","source_id_and_acronym":"NCT06528210","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • bicalutamide • triptorelin • goserelin acetate • Firmagon (degarelix) • Orgovyx (relugolix) • leuprolide acetate for depot suspension"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 08/01/2024","start_date":" 08/01/2024","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2024-07-30"},{"id":"cb5da6dd-a9b6-436a-acd6-01685f4f5bc2","acronym":"ETHAN","url":"https://clinicaltrials.gov/study/NCT05501704","created_at":"2022-08-15T12:10:47.553Z","updated_at":"2024-07-02T16:34:37.326Z","phase":"Phase 2","brief_title":"ETHAN - ET for Male BC","source_id_and_acronym":"NCT05501704 - ETHAN","lead_sponsor":"Jose Pablo Leone","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • anastrozole • Firmagon (degarelix) • Soltamox (tamoxifen citrate)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 10/11/2023","start_date":" 10/11/2023","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 04/01/2036","study_completion_date":" 04/01/2036","last_update_posted":"2024-06-07"},{"id":"c675e0ca-7f1a-4e3c-8775-d10e0e747837","acronym":"","url":"https://clinicaltrials.gov/study/NCT03358563","created_at":"2024-05-03T20:26:05.283Z","updated_at":"2025-02-25T16:31:15.404Z","phase":"Phase 1","brief_title":"Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer","source_id_and_acronym":"NCT03358563","lead_sponsor":"University of Wisconsin, Madison","biomarkers":" AR • EPCAM","pipe":"","alterations":" ","tags":["AR • EPCAM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • bicalutamide • Firmagon (degarelix)"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 01/17/2018","start_date":" 01/17/2018","primary_txt":" Primary completion: 08/10/2021","primary_completion_date":" 08/10/2021","study_txt":" Completion: 09/02/2022","study_completion_date":" 09/02/2022","last_update_posted":"2024-05-03"},{"id":"3a3871a3-373b-4120-a2fd-01f883ff6944","acronym":"","url":"https://clinicaltrials.gov/study/NCT06066437","created_at":"2023-10-04T15:10:45.245Z","updated_at":"2024-07-02T16:35:12.192Z","phase":"Phase 1/2","brief_title":"NeoAdjuvant Theranostic Lutetium Study: The Nautilus Trial","source_id_and_acronym":"NCT06066437","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" FOLH1","pipe":" | ","alterations":" FOLH1 expression","tags":["FOLH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Firmagon (degarelix)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 03/29/2024","start_date":" 03/29/2024","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-04-01"},{"id":"f412b2c8-e0f1-4eb7-8ad6-30e34f96ac6d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01542021","created_at":"2021-01-18T06:31:02.146Z","updated_at":"2024-07-02T16:35:17.074Z","phase":"","brief_title":"Androgen Deprivation Therapy Prior to Prostatectomy for Patients With Intermediate and High Risk Prostate Cancer","source_id_and_acronym":"NCT01542021","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CASP3","pipe":"","alterations":" ","tags":["CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Firmagon (degarelix)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 02/01/2012","start_date":" 02/01/2012","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-02-29"},{"id":"1bd14822-da3c-4dbb-9782-85f6d5deab4b","acronym":"PREDICT-RT","url":"https://clinicaltrials.gov/study/NCT04513717","created_at":"2021-01-18T21:37:58.373Z","updated_at":"2024-07-02T16:35:20.440Z","phase":"Phase 3","brief_title":"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial","source_id_and_acronym":"NCT04513717 - PREDICT-RT","lead_sponsor":"NRG Oncology","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • bicalutamide • apalutamide • triptorelin • goserelin acetate • flutamide • Firmagon (degarelix) • leuprolide acetate for depot suspension • Suprefact (buserelin acetate) • Yonsa (abiraterone acetate)"],"overall_status":"Recruiting","enrollment":" Enrollment 2478","initiation":"Initiation: 12/15/2020","start_date":" 12/15/2020","primary_txt":" Primary completion: 12/31/2033","primary_completion_date":" 12/31/2033","study_txt":" Completion: 12/31/2033","study_completion_date":" 12/31/2033","last_update_posted":"2024-02-07"},{"id":"516b31f5-466c-4410-8cae-2fcf87e0c0c4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01746849","created_at":"2021-01-18T07:39:24.877Z","updated_at":"2024-07-02T16:35:24.333Z","phase":"Phase 2","brief_title":"Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation","source_id_and_acronym":"NCT01746849","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD34 • CD4","pipe":" | ","alterations":" Chr t(15;17)","tags":["CD34 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(15;17)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Firmagon (degarelix) • thiotepa • leuprolide acetate for depot suspension • Kepivance (palifermin) • cyclophosphamide intravenous"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 12/01/2012","start_date":" 12/01/2012","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-01-05"},{"id":"0a4f94d2-46dc-4d75-9e6a-d30cc9f79e51","acronym":"CASPAR","url":"https://clinicaltrials.gov/study/NCT04455750","created_at":"2023-12-09T16:53:24.247Z","updated_at":"2024-07-02T16:35:27.217Z","phase":"Phase 3","brief_title":"A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy","source_id_and_acronym":"NCT04455750 - CASPAR","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" HRD","pipe":"","alterations":" ","tags":["HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • Rubraca (rucaparib) • goserelin acetate • Firmagon (degarelix) • leuprolide acetate for depot suspension"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 61","initiation":"Initiation: 02/19/2021","start_date":" 02/19/2021","primary_txt":" Primary completion: 05/15/2024","primary_completion_date":" 05/15/2024","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2023-12-04"},{"id":"86910daf-559d-4d54-870d-bff8653e3b13","acronym":"TASUC-Neo","url":"https://clinicaltrials.gov/study/NCT05839119","created_at":"2023-05-03T15:04:23.772Z","updated_at":"2024-07-02T16:35:34.468Z","phase":"Phase 1","brief_title":"Targeting Androgen Signaling in Urothelial Cell Carcinoma - Neoadjuvant","source_id_and_acronym":"NCT05839119 - TASUC-Neo","lead_sponsor":"Brown University","biomarkers":" AR","pipe":" | ","alterations":" AR positive","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • Firmagon (degarelix)"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 10/02/2023","start_date":" 10/02/2023","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2030","study_completion_date":" 01/01/2030","last_update_posted":"2023-10-06"},{"id":"76d00842-33fa-4faa-bc62-878fb551c3f0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02849990","created_at":"2021-01-18T13:59:26.821Z","updated_at":"2024-07-02T16:36:18.475Z","phase":"Phase 2","brief_title":"A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy","source_id_and_acronym":"NCT02849990","lead_sponsor":"University of Washington","biomarkers":" CASP3","pipe":"","alterations":" ","tags":["CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • prednisone • apalutamide • Firmagon (degarelix)"],"overall_status":"Completed","enrollment":" Enrollment 22","initiation":"Initiation: 03/09/2017","start_date":" 03/09/2017","primary_txt":" Primary completion: 12/10/2018","primary_completion_date":" 12/10/2018","study_txt":" Completion: 12/10/2020","study_completion_date":" 12/10/2020","last_update_posted":"2022-01-13"},{"id":"1d73f11b-1c4b-401f-88b2-b60b7980e821","acronym":"","url":"https://clinicaltrials.gov/study/NCT01751451","created_at":"2021-01-18T07:41:08.706Z","updated_at":"2024-07-02T16:36:20.502Z","phase":"Phase 2","brief_title":"3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy","source_id_and_acronym":"NCT01751451","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" PTEN","pipe":"","alterations":" ","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • Firmagon (degarelix)"],"overall_status":"Completed","enrollment":" Enrollment 124","initiation":"Initiation: 12/18/2012","start_date":" 12/18/2012","primary_txt":" Primary completion: 09/28/2020","primary_completion_date":" 09/28/2020","study_txt":" Completion: 09/28/2020","study_completion_date":" 09/28/2020","last_update_posted":"2021-11-19"},{"id":"c9290568-594d-4db4-8dee-d6569ecbe250","acronym":"ARNEO","url":"https://clinicaltrials.gov/study/NCT03080116","created_at":"2021-01-18T15:10:23.112Z","updated_at":"2024-07-02T16:36:36.870Z","phase":"Phase 2","brief_title":"Neoadjuvant Degarelix With or Without Apalutamide (ARN-509) Followed by Radical Prostatectomy","source_id_and_acronym":"NCT03080116 - ARNEO","lead_sponsor":"Universitaire Ziekenhuizen Leuven","biomarkers":" PTEN • FOLH1 • SPOP","pipe":" | ","alterations":" FOLH1 expression","tags":["PTEN • FOLH1 • SPOP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e apalutamide • Firmagon (degarelix)"],"overall_status":"Recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 03/28/2019","start_date":" 03/28/2019","primary_txt":" Primary completion: 06/30/2021","primary_completion_date":" 06/30/2021","study_txt":" Completion: 12/30/2021","study_completion_date":" 12/30/2021","last_update_posted":"2020-12-24"},{"id":"1cd187ec-4e86-400b-a0d1-c6694e1580af","acronym":"CaNCaP03","url":"https://clinicaltrials.gov/study/NCT02324998","created_at":"2021-01-18T11:01:50.119Z","updated_at":"2025-02-25T15:06:21.661Z","phase":"Phase 1","brief_title":"Study of Olaparib (± Degarelix) Given to Men With Intermediate/High Risk Prostate Cancer Before Prostatectomy","source_id_and_acronym":"NCT02324998 - CaNCaP03","lead_sponsor":"Cambridge University Hospitals NHS Foundation Trust","biomarkers":" RAD51 • CHEK1 • FANCD2","pipe":"","alterations":" ","tags":["RAD51 • CHEK1 • FANCD2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Firmagon (degarelix)"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 12/01/2016","start_date":" 12/01/2016","primary_txt":" Primary completion: 05/01/2019","primary_completion_date":" 05/01/2019","study_txt":" Completion: 05/01/2019","study_completion_date":" 05/01/2019","last_update_posted":"2019-08-29"},{"id":"2b0c47aa-7eb1-482c-8209-5d58feacf77b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02475057","created_at":"2021-01-18T11:54:59.787Z","updated_at":"2024-07-02T16:36:58.944Z","phase":"Phase 4","brief_title":"Endothelial Function in Prostate Cancer Patients on Degarelix vs. Luteinizing Hormone-Releasing Hormone Agonists","source_id_and_acronym":"NCT02475057","lead_sponsor":"Rabin Medical Center","biomarkers":" CRP • NPPB","pipe":"","alterations":" ","tags":["CRP • NPPB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Firmagon (degarelix)"],"overall_status":"Completed","enrollment":" Enrollment 80","initiation":"Initiation: 08/01/2015","start_date":" 08/01/2015","primary_txt":" Primary completion: 07/01/2018","primary_completion_date":" 07/01/2018","study_txt":" Completion: 06/01/2019","study_completion_date":" 06/01/2019","last_update_posted":"2019-06-12"},{"id":"0d2eebfc-9cc5-46fc-b803-33b31f1654e7","acronym":"","url":"https://clinicaltrials.gov/study/NCT02005887","created_at":"2021-01-18T09:11:21.452Z","updated_at":"2024-07-02T16:36:59.283Z","phase":"Phase 2","brief_title":"TRial on the Endocrine Activity of Neoadjuvant Degarelix","source_id_and_acronym":"NCT02005887","lead_sponsor":"ETOP IBCSG Partners Foundation","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • triptorelin • Firmagon (degarelix)"],"overall_status":"Completed","enrollment":" Enrollment 51","initiation":"Initiation: 02/01/2014","start_date":" 02/01/2014","primary_txt":" Primary completion: 08/25/2017","primary_completion_date":" 08/25/2017","study_txt":" Completion: 08/25/2017","study_completion_date":" 08/25/2017","last_update_posted":"2019-05-29"},{"id":"878d4b20-a0f2-47ba-92aa-d46b64eed99d","acronym":"","url":"https://clinicaltrials.gov/study/NCT01696877","created_at":"2021-01-29T07:03:47.403Z","updated_at":"2024-07-02T16:37:01.180Z","phase":"Phase 1/2","brief_title":"A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer","source_id_and_acronym":"NCT01696877","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" CD8 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • Firmagon (degarelix) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 01/18/2013","start_date":" 01/18/2013","primary_txt":" Primary completion: 08/01/2017","primary_completion_date":" 08/01/2017","study_txt":" Completion: 12/18/2018","study_completion_date":" 12/18/2018","last_update_posted":"2019-03-28"}]